Clinical trial results:
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Summary

EudraCT number	2017-001590-16
Trial protocol	DE IT
Global end of trial date	13 December 2019

Results information

Result version number	v2 (current)
This version publication date	03 March 2021
First version publication date	27 December 2020
Version creation reason	• New data added to full data set Additional data added for one endpoint.

Trial information

Trial identification

Sponsor protocol code	M15-563

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03391765
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AbbVie
Sponsor organisation address	AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6-4UB
Public contact	Global Medical Services, AbbVie, 001 8006339110, abbvieclinicaltrials@abbvie.com
Scientific contact	Global Medical Services, AbbVie, 001 8006339110, abbvieclinicaltrials@abbvie.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 December 2019
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	13 December 2019
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

This study was a Phase 2, randomized, double-blind, multiple-dose, multicenter, long-term extension of NCT02985879 (Study M15-562) in subjects with progressive supranuclear palsy (PSP). Those who completed the 52-week Treatment Period in Study M15-562 and met all entry criteria were eligible for enrollment into this study. This study planned for a Treatment Period of up to 5 years and a post-treatment follow-up visit approximately 20 weeks after the last dose of study drug (including participants who prematurely discontinued treatment). All participants received ABBV-8E12 as follows: those who received placebo in Study M15-562 were randomized, in a 1:1 ratio, to either 2000 or 4000 mg; those who received ABBV-8E12 at a dose of either 2000 or 4000 mg in Study M15-562 continued on the same dose in this study. This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.

Protection of trial subjects:

The subject voluntarily signed the Independent Ethics Committee (IEC)/Institutional Review Board (IRB) approved Informed Consent form, prior to the conduct of any study procedures, or, where applicable (i.e., countries other than Germany) for a given subject, the subject's legally authorized representative (LAR) signed the IEC/IRB approved Informed Consent form on behalf of the subject, prior to the conduct of any procedures. For Germany, where the subject's LAR is not permitted to sign the IEC/IRB approved Informed Consent form on behalf of the subject, evaluation by an independent psychiatrist was to be sought if the investigator who was evaluating the subject for inclusion in the study doubted the subject's cognitive ability to independently provide informed consent.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 January 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 100
Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	Canada: 12
Country: Number of subjects enrolled	Italy: 27
Worldwide total number of subjects	142
EEA total number of subjects	27

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	23
From 65 to 84 years	117
85 years and over	2

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

All enrolled participants

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Carer, Assessor, Subject, Investigator, Monitor, Data analyst

Blinding implementation details:

Investigators and subjects remained blinded to the treatment assignments from the parent Study M15-562 and all parties were blinded to the dose level of tilavonemab in this study, M15-563. The M15-563 study was not placebo-controlled.

Arms

Are arms mutually exclusive?	Yes
Arm title	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg

Arm description:

Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).

Arm type	Experimental
Investigational medicinal product name	ABBV-8E12
Investigational medicinal product code	
Other name	Tilavonemab
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.

Investigational medicinal product name	Placebo solution for IV infusion on Day 15
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.

Arm title	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg

Arm description:

Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).

Arm type	Experimental

Investigational medicinal product name	ABBV-8E12
Investigational medicinal product code	
Other name	Tilavonemab
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.

Investigational medicinal product name	Placebo solution for IV infusion on Day 15
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.

Arm title	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg

Arm description:

Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Arm type	Experimental
Investigational medicinal product name	ABBV-8E12
Investigational medicinal product code	
Other name	Tilavonemab
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.

Arm title	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg

Arm description:

Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Arm type	Experimental
Investigational medicinal product name	ABBV-8E12
Investigational medicinal product code	
Other name	Tilavonemab
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW >59 kg, 4.7 mL/min or 282 mL/hr.

Number of subjects in period 1	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg
Started	51	45	23
Completed	0	0	0
Not completed	51	45	23
Adverse event, non-fatal	2	-	-
Other, not specified	44	38	21
Withdrew consent	5	7	2

Number of subjects in period 1	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg
Started	23
Completed	0
Not completed	23
Adverse event, non-fatal	2
Other, not specified	16
Withdrew consent	5

Baseline characteristics

Reporting groups

Reporting group title	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg

Reporting group description:

Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).

Reporting group title	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg

Reporting group description:

Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).

Reporting group title	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg

Reporting group description:

Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Reporting group title	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg

Reporting group description:

Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Reporting group values	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg
Number of subjects	51	45	23
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	70.0	70.9	68.8
standard deviation	± 6.05	± 6.58	± 5.81
Gender categorical Units: Subjects			
Female	14	22	12
Male	37	23	11

Reporting group values	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg	Total	
Number of subjects	23	142	
Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	68.8		
standard deviation	± 5.78	-	
Gender categorical Units: Subjects			
Female	8	56	
Male	15	86	

End points

End points reporting groups

Reporting group title	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg

Reporting group description:

Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).

Reporting group title	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg

Reporting group description:

Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).

Reporting group title	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg

Reporting group description:

Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Reporting group title	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg

Reporting group description:

Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Primary: Change in Progressive Supranuclear Palsy Rating Scale (PSPRS) Total Score From Baseline to Week 52

End point title	Change in Progressive Supranuclear Palsy Rating Scale (PSPRS) Total Score From Baseline to Week 52[1]

End point description:

The PSPRS consists of 28 items grouped in six domains: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. Items are scored on a 0 to 4 scale, except for six items that are scored on a 0 to 2 scale, with the total score ranging from 0 to 100. Higher scores indicate more severe disability or movement abnormality. Positive values indicate worsening from baseline.

End point type	Primary

End point timeframe:

Baseline, Week 52

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not completed due to the early termination of the study.

End point values	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9[2]	6[3]	7[4]	6[5]
Units: units on a scale				
arithmetic mean (standard deviation)	14.4 (± 7.73)	2.3 (± 11.99)	13.1 (± 6.87)	4.2 (± 6.40)

Notes:

[2] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[3] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[4] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[5] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline to Week 52 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living)

End point title	Mean Change From Baseline to Week 52 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living)

End point description:

The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. Higher scores are associated with more disability. Positive values indicate worsening from baseline.

End point type	Secondary

End point timeframe:

Baseline, Week 52

End point values	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9[6]	6[7]	7[8]	6[9]
Units: units on a scale				
arithmetic mean (standard deviation)	6.9 (± 4.37)	3.2 (± 5.27)	5.6 (± 5.68)	7.3 (± 6.28)

Notes:

[6] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[7] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[8] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[9] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

Statistical analyses

No statistical analyses for this end point

Secondary: Change in Clinical Global Impression of Severity (CGI-C) Score From Baseline to Week 52

End point title	Change in Clinical Global Impression of Severity (CGI-C) Score From Baseline to Week 52

End point description:

The Clinical Global Impression of Change (CGI-C) score is a clinician's rating scale for assessing Global Improvement of Change. The CGI-C rates improvement by 7 categories: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), very much worse (7). The CGI-C score ranges from 1 to 7, with lower scores indicating improvement.

End point type	Secondary

End point timeframe:

Baseline, Week 52

End point values	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50[10]	42[11]	22[12]	23[13]
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline of M15-563; n=50,42,22,23	5.0 (± 0.89)	4.8 (± 0.92)	4.9 (± 0.92)	5.0 (± 0.91)
Week 52 of M15-563, n= 8,6,7,5	5.1 (± 0.64)	5.2 (± 0.98)	5.9 (± 0.90)	5.4 (± 1.14)

Notes:

[10] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[11] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[12] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[13] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline to Week 52 in Schwab and England Activities of Daily Living Scale (SEADL)

End point title	Mean Change From Baseline to Week 52 in Schwab and England Activities of Daily Living Scale (SEADL)

End point description:

The Schwab and England Activities of Daily Living (SEADL) scale consists of ten items intended to evaluate the daily life activities of a participant. The SEADL is composed of two sections: the first is a self-reported questionnaire in which participants grade their own daily life activities, such as dressing, using the toilet, resting, eating, and social activities (subjective assessment), and the second is an assessment of motor functions, such as postural balance, speaking, rigidity, and tremors, conducted by a clinician (objective assessment). It is a percentage scale divided into deciles, and the results are reported between 0% (bedridden) and 100% (healthy). Negative values indicate worsening from baseline.

End point type	Secondary

End point timeframe:

Baseline, Week 52

End point values	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9[14]	6[15]	7[16]	5[17]
Units: units on a scale				
arithmetic mean (standard deviation)	-13.3 (± 14.14)	-13.3 (± 12.11)	-10.0 (± 14.14)	-18.0 (± 13.04)

Notes:

[14] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[15] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[16] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[17] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline to Week 52 in Clinical Global Impression of Severity (CGI-S) Score

End point title	Mean Change From Baseline to Week 52 in Clinical Global Impression of Severity (CGI-S) Score

End point description:

The CGI-S is a clinician's rating of disease severity. The CGI-S rates severity of illness on a 7-point scale, using a range of responses from 1 (normal) through 7 (the most severely ill). This rating is based upon observed and reported symptoms, behavior, and function in the past 7 days. Positive values indicate worsening from baseline.

End point type	Secondary

End point timeframe:

Baseline, Week 52

End point values	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8[18]	6[19]	7[20]	5[21]
Units: units on a scale				
arithmetic mean (standard deviation)	0.6 (± 0.52)	1.3 (± 0.82)	1.3 (± 0.49)	0.6 (± 1.82)

Notes:

[18] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[19] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and

Week 52

[20] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52
[21] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

Statistical analyses

No statistical analyses for this end point

Secondary: Patient Global Impression of Change Score (PGI-C) Score From Baseline to Week 52

End point title	Patient Global Impression of Change Score (PGI-C) Score From Baseline to Week 52

End point description:

The PGI-C is a participant's rating of the change in their PSP-related symptoms since initiation of study drug. Participants rated their change in status using the following 7-point scale: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse.

End point type	Secondary

End point timeframe:

Baseline, Week 52

End point values	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48[22]	43[23]	23[24]	23[25]
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline of M15-563; n=48,43,23,23	5.0 (± 1.03)	5.1 (± 1.04)	5.2 (± 1.30)	5.3 (± 1.15)
Week 52 of M15-563, n=9,6,7,6	4.9 (± 1.62)	4.7 (± 1.51)	5.4 (± 0.53)	5.3 (± 1.37)

Notes:

[22] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52
[23] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52
[24] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52
[25] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline to Week 52 in Progressive Supranuclear Palsy Staging System Score (PSP-SS) Score

End point title	Mean Change From Baseline to Week 52 in Progressive Supranuclear Palsy Staging System Score (PSP-SS) Score

End point description:

The Progressive Supranuclear Palsy Rating Scale (PSPRS) consists of 28 items grouped in six domains: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. Items are scored on a 0 to 4 scale, except for four items that are scored on a 0 to 2 scale, with the total score ranging from 0 to 100. Higher scores indicate more severe disability or movement abnormality. The PSP-SS score is a composite of the dysphagia and gait items from the PSPRS. Positive values indicate worsening from baseline.

End point type	Secondary

End point timeframe:

Baseline, Week 52

End point values	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9[26]	6[27]	7[28]	6[29]
Units: units on a scale				
arithmetic mean (standard deviation)	2.4 (± 1.74)	-0.2 (± 2.23)	2.0 (± 2.83)	1.0 (± 2.10)

Notes:

[26] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[27] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[28] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

[29] - ITT:subjects who rcvd any dose of study drug in this study w/ available data at baseline and Week 52

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Time to Loss of Ability to Walk Independently as Measured by Progressive Supranuclear Palsy Rating Scale (PSPRS) Item 26

End point title	Mean Time to Loss of Ability to Walk Independently as Measured by Progressive Supranuclear Palsy Rating Scale (PSPRS) Item 26

End point description:

The PSPRS consists of 28 items grouped in six domains: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. Items are scored on a 0 to 4 scale, except for four items that are scored on a 0 to 2 scale, with the total score ranging from 0 to 100. Higher scores indicate more severe disability or movement abnormality. Item 26 pertains to gait, scored as either 0 (normal); 1 (slightly wide-based or irregular or slight pulsion on turns); 2 (must walk slowly or occasionally use walls or helper to avoid falling, especially on turns); 3 (must use assistance all or almost all the time); or 4 (unable to walk, even with walker; may be able to transfer).

End point type	Secondary

End point timeframe:

From Baseline to Week 52

End point values	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	51[30]	45[31]	23[32]	23[33]
Units: days				
median (confidence interval 95%)	84.0 (29.0 to 86.0)	85.0 (84.0 to 91.0)	85.0 (42.0 to 91.0)	84.0 (64.0 to 86.0)

Notes:

[30] - ITT dataset: subjects who rcvd any dose of study drug in Study M15-563 and those with available data

[31] - ITT dataset: subjects who rcvd any dose of study drug in Study M15-563 and those with available data

[32] - ITT dataset: subjects who rcvd any dose of study drug in Study M15-563 and those with available data

[33] - ITT dataset: subjects who rcvd any dose of study drug in Study M15-563 and those with available data

Statistical analyses

No statistical analyses for this end point

Adverse events information

Timeframe for reporting adverse events:

Treatment-emergent adverse events and serious adverse events collected from 1st dose of study drug until 20 wks after discontinuation, up to 98 wks. Serious adverse events and protocol-related nonserious adverse events collected from informed consent.

Adverse event reporting additional description:

TEAEs and SAEs are defined as any AE or SAE with onset or worsening reported by a participant from the time that the first dose of study is administered until 20 weeks (approximately 5 half-lives) have elapsed following discontinuation of study drug. TEAEs were collected whether elicited or spontaneously reported by the participant.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	22.0

Reporting groups

Reporting group title	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg

Reporting group description:

Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).

Reporting group title	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg

Reporting group description:

ntravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Reporting group title	M15-562 ABBV-8E12 4000 mg / M15-563 ABBV-8E12 4000 mg

Reporting group description:

Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).

Reporting group title	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg

Reporting group description:

Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Serious adverse events	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg / M15-563 ABBV-8E12 4000 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 51 (19.61%)	3 / 23 (13.04%)	10 / 45 (22.22%)
number of deaths (all causes)	5	1	5
number of deaths resulting from adverse events	4	1	3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
COLORECTAL CANCER			

subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LYMPHOMA			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
CERVICAL VERTEBRAL FRACTURE			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CLAVICLE FRACTURE			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FALL			
subjects affected / exposed	2 / 51 (3.92%)	0 / 23 (0.00%)	2 / 45 (4.44%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RIB FRACTURE			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
CARDIAC ARREST			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

CARDIO-RESPIRATORY ARREST			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Nervous system disorders			
LETHARGY			
subjects affected / exposed	0 / 51 (0.00%)	1 / 23 (4.35%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PARTIAL SEIZURES			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PROGRESSIVE SUPRANUCLEAR PALSY			
subjects affected / exposed	0 / 51 (0.00%)	1 / 23 (4.35%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COMPLICATION ASSOCIATED WITH DEVICE			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEATH			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Gastrointestinal disorders			
INTESTINAL OBSTRUCTION			

subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
APNOEA			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
ASPIRATION			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPNOEA			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
PNEUMONIA ASPIRATION			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	3 / 45 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 51 (0.00%)	1 / 23 (4.35%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
MUSCULOSKELETAL PAIN			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
INFLUENZA			

subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
KLEBSIELLA INFECTION			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
subjects affected / exposed	3 / 51 (5.88%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
POST PROCEDURAL SEPSIS			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
subjects affected / exposed	2 / 51 (3.92%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 23 (30.43%)		
number of deaths (all causes)	2		
number of deaths resulting from	2		

adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
COLORECTAL CANCER			
subjects affected / exposed	1 / 23 (4.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
LYMPHOMA			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
CERVICAL VERTEBRAL FRACTURE			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CLAVICLE FRACTURE			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FALL			
subjects affected / exposed	1 / 23 (4.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
HIP FRACTURE			
subjects affected / exposed	1 / 23 (4.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
RIB FRACTURE			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
CARDIAC ARREST			

subjects affected / exposed	1 / 23 (4.35%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
CARDIO-RESPIRATORY ARREST				
subjects affected / exposed	0 / 23 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nervous system disorders				
LETHARGY				
subjects affected / exposed	0 / 23 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PARTIAL SEIZURES				
subjects affected / exposed	1 / 23 (4.35%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
PROGRESSIVE SUPRANUCLEAR PALSY				
subjects affected / exposed	0 / 23 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General disorders and administration site conditions				
ASTHENIA				
subjects affected / exposed	0 / 23 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COMPLICATION ASSOCIATED WITH DEVICE				
subjects affected / exposed	1 / 23 (4.35%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
DEATH				

subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
INTESTINAL OBSTRUCTION			
subjects affected / exposed	1 / 23 (4.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
APNOEA			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ASPIRATION			
subjects affected / exposed	1 / 23 (4.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
DYSPNOEA			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMONIA ASPIRATION			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
MUSCULOSKELETAL PAIN			

subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
INFLUENZA			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
KLEBSIELLA INFECTION			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMONIA			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
POST PROCEDURAL SEPSIS			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SEPSIS			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 23 (4.35%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	M15-562 ABBV-8E12 2000 mg/ M15-563 ABBV-8E12 2000 mg	M15-562 Placebo/M15-563 ABBV-8E12 2000 mg	M15-562 ABBV-8E12 4000 mg / M15-563 ABBV-8E12 4000 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 51 (35.29%)	6 / 23 (26.09%)	16 / 45 (35.56%)
Investigations			
WEIGHT DECREASED			
subjects affected / exposed	2 / 51 (3.92%)	1 / 23 (4.35%)	0 / 45 (0.00%)
occurrences (all)	2	2	0
Injury, poisoning and procedural complications			
CHEST INJURY			
subjects affected / exposed	0 / 51 (0.00%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
CONTUSION			
subjects affected / exposed	2 / 51 (3.92%)	1 / 23 (4.35%)	3 / 45 (6.67%)
occurrences (all)	3	2	4
FALL			
subjects affected / exposed	9 / 51 (17.65%)	2 / 23 (8.70%)	7 / 45 (15.56%)
occurrences (all)	13	8	9
LIP INJURY			
subjects affected / exposed	1 / 51 (1.96%)	1 / 23 (4.35%)	1 / 45 (2.22%)
occurrences (all)	1	1	1
SKIN ABRASION			
subjects affected / exposed	3 / 51 (5.88%)	2 / 23 (8.70%)	0 / 45 (0.00%)
occurrences (all)	3	2	0
SKIN LACERATION			
subjects affected / exposed	5 / 51 (9.80%)	1 / 23 (4.35%)	3 / 45 (6.67%)
occurrences (all)	5	4	3
Vascular disorders			
HYPOTENSION			
subjects affected / exposed	1 / 51 (1.96%)	2 / 23 (8.70%)	0 / 45 (0.00%)
occurrences (all)	1	2	0
General disorders and administration site conditions			

ASTHENIA			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
PYREXIA			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
CONSTIPATION			
subjects affected / exposed	4 / 51 (7.84%)	0 / 23 (0.00%)	2 / 45 (4.44%)
occurrences (all)	4	0	2
DYSPHAGIA			
subjects affected / exposed	2 / 51 (3.92%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences (all)	2	0	1
Psychiatric disorders			
ANXIETY			
subjects affected / exposed	0 / 51 (0.00%)	2 / 23 (8.70%)	4 / 45 (8.89%)
occurrences (all)	0	2	4
Musculoskeletal and connective tissue disorders			
PAIN IN EXTREMITY			
subjects affected / exposed	1 / 51 (1.96%)	0 / 23 (0.00%)	1 / 45 (2.22%)
occurrences (all)	1	0	1
Infections and infestations			
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	2 / 51 (3.92%)	2 / 23 (8.70%)	1 / 45 (2.22%)
occurrences (all)	2	2	1
URINARY TRACT INFECTION			
subjects affected / exposed	7 / 51 (13.73%)	1 / 23 (4.35%)	7 / 45 (15.56%)
occurrences (all)	11	1	10

Non-serious adverse events	M15-562 Placebo/M15-563 ABBV-8E12 4000 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	16 / 23 (69.57%)		
Investigations			
WEIGHT DECREASED			
subjects affected / exposed	3 / 23 (13.04%)		
occurrences (all)	3		

Injury, poisoning and procedural complications			
CHEST INJURY			
subjects affected / exposed	2 / 23 (8.70%)		
occurrences (all)	2		
CONTUSION			
subjects affected / exposed	2 / 23 (8.70%)		
occurrences (all)	5		
FALL			
subjects affected / exposed	9 / 23 (39.13%)		
occurrences (all)	20		
LIP INJURY			
subjects affected / exposed	2 / 23 (8.70%)		
occurrences (all)	2		
SKIN ABRASION			
subjects affected / exposed	3 / 23 (13.04%)		
occurrences (all)	3		
SKIN LACERATION			
subjects affected / exposed	6 / 23 (26.09%)		
occurrences (all)	9		
Vascular disorders			
HYPOTENSION			
subjects affected / exposed	0 / 23 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	2 / 23 (8.70%)		
occurrences (all)	2		
PYREXIA			
subjects affected / exposed	3 / 23 (13.04%)		
occurrences (all)	3		
Gastrointestinal disorders			
CONSTIPATION			
subjects affected / exposed	2 / 23 (8.70%)		
occurrences (all)	2		
DYSPHAGIA			

subjects affected / exposed occurrences (all)	3 / 23 (13.04%) 3		
Psychiatric disorders ANXIETY subjects affected / exposed occurrences (all)	 1 / 23 (4.35%) 1		
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY subjects affected / exposed occurrences (all)	 3 / 23 (13.04%) 3		
Infections and infestations UPPER RESPIRATORY TRACT INFECTION subjects affected / exposed occurrences (all) URINARY TRACT INFECTION subjects affected / exposed occurrences (all)	 0 / 23 (0.00%) 0 2 / 23 (8.70%) 2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 March 2018	Amendment 1 ● Updated Overall Study Design and Plan: Description to reflect the anticipated number of participating sites due to an increase in the number of subjects, i.e., increasing from 180 to 330 ● Updated Inclusion Criteria and Section 9.3, Subject Information and Consent, to address informed consent procedures specific to Germany ● Updated Treatments Administered Section, to reflect the infusion rate in lieu of a length of infusion in minutes/hours ● Updated Identity of Investigational Product, to include a 1000 mg/10 mL formulation, in addition to the 300 mg/15 mL vial ● Update Preparation/Reconstitution of Dosage Form, Section 5.5.5, Blinding, and Section 5.5.7, Drug Accountability, to provide additional guidance on investigational product blinding and accountability.
21 February 2019	Amendment 2 ● Updated Inclusion Criteria to remove the need for subjects to sign an assent form ● Updated 12-Lead Electrocardiogram section, to remove the requirement for postdose ECG on Day 1 ● Updated Magnetic Resonance Imaging section to remove the requirement that study entry MRI must be completed after other relevant procedures have been completed ● Updated Magnetic Resonance Imaging section to add that if a subject cannot undergo MRI for clinical reasons, the AbbVie TA MD should be consulted for approval ● Updated Lumbar Puncture section to add that subjects who are unable to undergo an LP may be enrolled with permission of the AbbVie TA MD without the requirement of an LP during the study ● Updated Diagnostic Tools and Rating Scales to add a Treatment Satisfaction Questionnaire for Medication, PSP Caregiver Questionnaires, and the BioStamp nPoint device ● Updated Treatments Administered section to align the infusion rates in this extension study with those of the parent study (Study M15-562) ● Updated Storage and Disposition of Study Drug section, to clarify the requirements for reporting temperature excursions ● Updated Reporting section to correct the time frame for which product complaints must be reported ● Updated Overall Study Design and Plan: Description, to add a digital BioStamp substudy

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported